In late trade on Tuesday, the S&P/ASX 200 Index (ASX: XJO) is on track to end the session with a strong gain. At the time of writing, the benchmark index is up 1.6% to 8,715.9 points.
Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:
Image source: Getty Images
Challenger Ltd (ASX: CGF)
The Challenger share price is down 3.5% to $8.05. This is despite news that the company has signed a strategic capital partnership with Bank of Queensland Ltd (ASX: BOQ). The Challenger partnership includes a whole-of-loan sale and a forward flow arrangement for equipment finance assets. Challenger's chief investment officer, Damian Graham, said: "We're pleased to have partnered with BOQ on this whole-of-loan sale and forward flow arrangement for equipment finance assets. The transaction establishes a strategic partnership with BOQ and provides Challenger with access to a high-quality, seasoned and highly diversified loan portfolio that will deliver attractive risk-adjusted returns for Challenger and institutional investors."
Lotus Resources Ltd (ASX: LOT)
The Lotus Resources share price is down 3.5% to $1.31. This has been driven by the release of a uranium production update this morning. The company revealed that it will replace two newly installed electrical control panels in the drying and packaging area of its Kayelekera uranium mine due to fire damage sustained on Saturday. The incident is expected to result in production downtime of approximately three weeks for repairs, testing, and recommissioning. Lotus' managing director, Greg Bittar, commented: "Despite this delay, the progress in positioning Kayelekera for steady-state production this quarter has been encouraging, and we still expect to achieve this in Q2 CY2026. Reagent planning and inventories, mill performance and other key processing parameters all provide visibility on this."
Mesoblast Ltd (ASX: MSB)
The Mesoblast share price is down 6.5% to $1.99. This follows the release of a sales update from the biotech company today. Mesoblast revealed that net sales for Ryoncil reached US$30.3 million in the third quarter. This means that revenue since the Ryoncil launch is now approaching US$100 million. This may be softer than some investors were expecting. Ryoncil is the only FDA-approved cell therapy for children under 12 with steroid-refractory acute graft-versus-host disease.
Wildcat Resources Ltd (ASX: WC8)
The Wildcat Resources share price is down almost 4% to 37.5 cents. This morning, the lithium explorer and developer released a drilling update. It revealed a ~300 metres northerly extension of interpreted spodumene mineralisation at Bolt Cutter Central. It is located ~10km west of Wildcat's Tabba Tabba Project in the Pilbara region of Western Australia.
